{"id":"oral-sorafenib","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Hand-foot skin reaction"},{"rate":"25-35","effect":"Diarrhea"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Hypertension"},{"rate":"15-20","effect":"Rash"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL1200485","moleculeType":"Small molecule","molecularWeight":"637.04"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sorafenib inhibits multiple serine/threonine and receptor tyrosine kinases, including RAF kinase (involved in the MAPK pathway), VEGFR-2 and VEGFR-3 (which promote tumor angiogenesis), and PDGFR-β (which supports tumor vasculature). By blocking these pathways, sorafenib reduces both direct tumor cell growth and the formation of new blood vessels that tumors depend on for survival.","oneSentence":"Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:45.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"},{"name":"Renal cell carcinoma"},{"name":"Differentiated thyroid cancer"}]},"trialDetails":[{"nctId":"NCT02298348","phase":"PHASE1","title":"Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2015-10-08","conditions":"Neuroblastoma","enrollment":18},{"nctId":"NCT07463651","phase":"PHASE3","title":"MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-05-01","conditions":"Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT)","enrollment":594},{"nctId":"NCT06309485","phase":"PHASE2","title":"Phase 2 Study of WGI-0301 for Advanced HCC","status":"RECRUITING","sponsor":"Zhejiang Haichang Biotech Co., Ltd.","startDate":"2024-07-31","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":60},{"nctId":"NCT05468359","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-11-07","conditions":"Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor","enrollment":64},{"nctId":"NCT07463248","phase":"PHASE2","title":"PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Wang Xin","startDate":"2026-03-05","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":64},{"nctId":"NCT00939627","phase":"PHASE2","title":"Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07","conditions":"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer","enrollment":55},{"nctId":"NCT07449065","phase":"","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI)","enrollment":324},{"nctId":"NCT07425808","phase":"PHASE2, PHASE3","title":"FLT3-ITD Targeted Therapy in Fit AML Patients","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2026-12-01","conditions":"AML (Acute Myeloid Leukemia)","enrollment":230},{"nctId":"NCT04039607","phase":"PHASE3","title":"A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-09-30","conditions":"Hepatocellular Carcinoma","enrollment":732},{"nctId":"NCT05669339","phase":"PHASE2","title":"AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-12-02","conditions":"Hepatocellular Carcinoma","enrollment":12},{"nctId":"NCT04770896","phase":"PHASE3","title":"A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-04-26","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":557},{"nctId":"NCT01903694","phase":"PHASE3","title":"Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2010-03","conditions":"Child-Pugh A Hepatocellular Carcinoma","enrollment":474},{"nctId":"NCT05673824","phase":"PHASE2","title":"Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.","status":"COMPLETED","sponsor":"Fudan University","startDate":"2023-01-03","conditions":"Nephrotoxicity","enrollment":76},{"nctId":"NCT00989469","phase":"PHASE1, PHASE2","title":"Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2009-02","conditions":"Metastatic Colorectal Cancer","enrollment":64},{"nctId":"NCT01715441","phase":"PHASE2","title":"Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2012-09","conditions":"Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors","enrollment":173},{"nctId":"NCT01730937","phase":"PHASE3","title":"Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2013-04","conditions":"Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer","enrollment":193},{"nctId":"NCT00826540","phase":"PHASE2","title":"Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer","enrollment":83},{"nctId":"NCT05117957","phase":"PHASE2","title":"Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study","status":"COMPLETED","sponsor":"Bo Hyun Kim","startDate":"2022-03-08","conditions":"Advanced Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT01658878","phase":"PHASE1, PHASE2","title":"An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-10-30","conditions":"Hepatocellular Carcinoma","enrollment":657},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":"Rhabdomyosarcoma","enrollment":115},{"nctId":"NCT03247088","phase":"PHASE1, PHASE2","title":"Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-30","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":74},{"nctId":"NCT03755791","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2018-06-10","conditions":"Hepatocellular Carcinoma","enrollment":837},{"nctId":"NCT01187199","phase":"PHASE1","title":"Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-08-19","conditions":"Advanced Cancer","enrollment":278},{"nctId":"NCT03412773","phase":"PHASE3","title":"A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-12-18","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":684},{"nctId":"NCT07203352","phase":"PHASE3","title":"Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":154},{"nctId":"NCT03037437","phase":"PHASE2","title":"Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-02-16","conditions":"Hepatocellular Cancer","enrollment":64},{"nctId":"NCT00265798","phase":"PHASE2","title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-14","conditions":"Gastrointestinal Stromal Tumor","enrollment":38},{"nctId":"NCT05822752","phase":"PHASE2","title":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-09-21","conditions":"Hepatocellular Carcinoma","enrollment":130},{"nctId":"NCT01141309","phase":"PHASE2","title":"Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-06","conditions":"Thyroid Cancer","enrollment":41},{"nctId":"NCT06972641","phase":"PHASE2, PHASE3","title":"Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-10","conditions":"AML, MDS","enrollment":126},{"nctId":"NCT01754987","phase":"PHASE1, PHASE2","title":"A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2012-09","conditions":"Metastatic Hepatocellular Carcinoma, Advanced Liver Cancer","enrollment":5},{"nctId":"NCT02939807","phase":"PHASE2","title":"A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Medical University of South Carolina","startDate":"2019-09-30","conditions":"Carcinoma, Hepatocellular","enrollment":""},{"nctId":"NCT04000737","phase":"PHASE2","title":"YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Yiviva Inc.","startDate":"2020-01-10","conditions":"Advanced Hepatocellular Carcinoma","enrollment":62},{"nctId":"NCT05873244","phase":"PHASE2","title":"CXD101 in Immunotherapy-related Liver Cancer","status":"RECRUITING","sponsor":"Stephen Chan Lam","startDate":"2023-08-21","conditions":"HCC","enrollment":44},{"nctId":"NCT06797427","phase":"EARLY_PHASE1","title":"A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers","status":"COMPLETED","sponsor":"Disruptive Pharma","startDate":"2025-02-10","conditions":"Healthy","enrollment":12},{"nctId":"NCT04710641","phase":"PHASE2","title":"Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone","status":"COMPLETED","sponsor":"Mina Alpha Limited","startDate":"2022-01-01","conditions":"Hepatocellular Carcinoma, Hepatitis B, Hepatitis C","enrollment":8},{"nctId":"NCT04709380","phase":"PHASE3","title":"Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT","status":"TERMINATED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-03-02","conditions":"Radiotherapy, Toripalimab, Sorafenib","enrollment":36},{"nctId":"NCT04344158","phase":"PHASE3","title":"A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-08-11","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":648},{"nctId":"NCT06592989","phase":"","title":"A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-30","conditions":"Pancreatic Neuroendocrine Neoplasm, Sorafenib, Gefitinib","enrollment":20},{"nctId":"NCT06763666","phase":"PHASE4","title":"CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-02","conditions":"Relapsed/Refractory AML","enrollment":172},{"nctId":"NCT03477175","phase":"PHASE2","title":"Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-08-16","conditions":"Solid Tumors","enrollment":40},{"nctId":"NCT01101906","phase":"PHASE2","title":"A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2011-01-10","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":23},{"nctId":"NCT00687596","phase":"PHASE2","title":"Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2008-08-01","conditions":"Hepatocellular Carcinoma","enrollment":52},{"nctId":"NCT02856126","phase":"PHASE3","title":"HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-08","conditions":"Hepatocellular Carcinoma","enrollment":214},{"nctId":"NCT04763408","phase":"","title":"A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2021-04-09","conditions":"Carcinoma, Hepatocellular","enrollment":335},{"nctId":"NCT01817751","phase":"PHASE2","title":"Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2013-04-11","conditions":"Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma","enrollment":47},{"nctId":"NCT06320301","phase":"PHASE2","title":"Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-01","conditions":"Biliary Tract Cancer, Gemox Chemotherapy","enrollment":43},{"nctId":"NCT00096434","phase":"PHASE2","title":"Sorafenib in Treating Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-09","conditions":"Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer","enrollment":23},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04103398","phase":"PHASE3","title":"TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2019-10-02","conditions":"Hepatocellular Carcinoma, Sorafenib, Transarterial Chemoembolization","enrollment":162},{"nctId":"NCT03764293","phase":"PHASE3","title":"A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-06-10","conditions":"Locally Advanced or Metastatic and Unresectable HCC","enrollment":543},{"nctId":"NCT04560894","phase":"PHASE2, PHASE3","title":"SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2020-11-11","conditions":"Hepatocellular Carcinoma","enrollment":405},{"nctId":"NCT00634634","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2008-08-11","conditions":"Metastatic Breast Cancer","enrollment":52},{"nctId":"NCT00496756","phase":"PHASE2","title":"Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2007-03-01","conditions":"Kidney Cancer","enrollment":14},{"nctId":"NCT03434379","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-03-15","conditions":"Carcinoma, Hepatocellular","enrollment":558},{"nctId":"NCT04135690","phase":"PHASE2","title":"HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-10-20","conditions":"Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT00093457","phase":"PHASE2","title":"Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2004-08-10","conditions":"Prostate Cancer","enrollment":28},{"nctId":"NCT00516828","phase":"PHASE1, PHASE2","title":"Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-11-27","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":21},{"nctId":"NCT05313958","phase":"PHASE2, PHASE3","title":"Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-01","conditions":"Leukemia, Monocytic, Acute, Pediatric AML","enrollment":43},{"nctId":"NCT03722498","phase":"PHASE2","title":"Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT00064350","phase":"PHASE2","title":"Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-06-28","conditions":"Lung Cancer","enrollment":342},{"nctId":"NCT00813293","phase":"PHASE2","title":"Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2009-06","conditions":"Hepatocellular Cancer","enrollment":20},{"nctId":"NCT05889949","phase":"","title":"Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-06-01","conditions":"Radiomics, Hepatocellular Carcinoma (HCC), Transcatheter Arterial Chemoembolization (TACE)","enrollment":200},{"nctId":"NCT03586973","phase":"PHASE2","title":"A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-08-06","conditions":"Advanced Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT04992143","phase":"PHASE2","title":"TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-08-20","conditions":"BCLC Stage C Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT04387695","phase":"PHASE3","title":"SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-04-30","conditions":"Unresectable Hepatocellular Carcinoma, Portal Vein Thrombosis","enrollment":54},{"nctId":"NCT03236649","phase":"PHASE3","title":"The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects","status":"TERMINATED","sponsor":"Beijing Shenogen Biomedical Co., Ltd","startDate":"2017-09-20","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":89},{"nctId":"NCT03582618","phase":"PHASE2","title":"CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"TaiRx, Inc.","startDate":"2018-07-12","conditions":"Hepatocellular Carcinoma, Advanced Cancer","enrollment":12},{"nctId":"NCT01180959","phase":"PHASE2","title":"Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-04-14","conditions":"Liver Cancer","enrollment":45},{"nctId":"NCT05601895","phase":"","title":"The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-10-01","conditions":"Acute Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":60},{"nctId":"NCT05596968","phase":"","title":"The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-10-01","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":37},{"nctId":"NCT05596981","phase":"","title":"The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-10-01","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":60},{"nctId":"NCT02024087","phase":"PHASE1, PHASE2","title":"Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2014-08-04","conditions":"Advanced Adult Hepatocellular Carcinoma","enrollment":21},{"nctId":"NCT02349867","phase":"PHASE1","title":"Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2015-01-29","conditions":"Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer","enrollment":23},{"nctId":"NCT05535998","phase":"","title":"TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT","status":"COMPLETED","sponsor":"Yunfei Yuan","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":743},{"nctId":"NCT04985136","phase":"PHASE3","title":"A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-09-26","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":1},{"nctId":"NCT01988493","phase":"PHASE1, PHASE2","title":"Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-01-06","conditions":"Carcinoma, Hepatocellular","enrollment":117},{"nctId":"NCT02115373","phase":"PHASE1, PHASE2","title":"c-Met Second-Line Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-05-18","conditions":"Carcinoma, Hepatocellular","enrollment":66},{"nctId":"NCT01582009","phase":"PHASE1, PHASE2","title":"Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2010-03","conditions":"Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer","enrollment":26},{"nctId":"NCT01253070","phase":"PHASE2","title":"Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-04-01","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","enrollment":54},{"nctId":"NCT02575339","phase":"PHASE1, PHASE2","title":"MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Kathy Miller","startDate":"2016-07-18","conditions":"Hepatocellular Carcinoma, Liver Cancer, HCC","enrollment":11},{"nctId":"NCT05420922","phase":"","title":"Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-11-01","conditions":"Hepatocellular Carcinoma, Programmed Cell Death 1, Effects of Immunotherapy","enrollment":2000},{"nctId":"NCT00602576","phase":"PHASE2","title":"Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2005-01-01","conditions":"Melanoma (Skin)","enrollment":169},{"nctId":"NCT04788420","phase":"","title":"Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2012-01-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Hematopoietic Stem Cell Transplantation","enrollment":456},{"nctId":"NCT00867321","phase":"PHASE1, PHASE2","title":"Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-04","conditions":"Liver Cancer","enrollment":24},{"nctId":"NCT01761266","phase":"PHASE3","title":"A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2013-03-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":954},{"nctId":"NCT00600015","phase":"PHASE2","title":"Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2008-02","conditions":"Non-Small Cell Lung Cancer","enrollment":166},{"nctId":"NCT01724606","phase":"PHASE1","title":"Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-11-05","conditions":"Breast Cancer, Brain Metastases","enrollment":21},{"nctId":"NCT02178358","phase":"PHASE2","title":"A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-08-08","conditions":"Hepatocellular Carcinoma","enrollment":132},{"nctId":"NCT00096200","phase":"PHASE2","title":"Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-08","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":44},{"nctId":"NCT01248247","phase":"PHASE2","title":"BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-06-02","conditions":"Lung Cancer","enrollment":334},{"nctId":"NCT04476329","phase":"PHASE2","title":"Optimization for Regorafenib in HCC","status":"TERMINATED","sponsor":"SC Liver Research Consortium, LLC","startDate":"2021-01-21","conditions":"Hepatocellular Carcinoma","enrollment":7},{"nctId":"NCT04752527","phase":"PHASE2","title":"Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-02-20","conditions":"Acute Myeloid Leukemia, Adult","enrollment":42},{"nctId":"NCT04674345","phase":"PHASE2, PHASE3","title":"Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2020-12-15","conditions":"Acute Leukemia, Relapse, Hematopoietic Stem Cell Transplantation","enrollment":346},{"nctId":"NCT01620216","phase":"PHASE2","title":"Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2012-05-11","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia","enrollment":12},{"nctId":"NCT01141478","phase":"NA","title":"Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria","status":"TERMINATED","sponsor":"Loma Linda University","startDate":"2010-09-08","conditions":"Carcinoma, Hepatocellular","enrollment":8},{"nctId":"NCT04127396","phase":"PHASE4","title":"Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2019-09-01","conditions":"Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus","enrollment":72},{"nctId":"NCT04926532","phase":"PHASE1, PHASE2","title":"Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2019-08-01","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT01032850","phase":"PHASE2","title":"Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2009-09","conditions":"Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT01271504","phase":"PHASE1, PHASE2","title":"E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-07-19","conditions":"Hepatocellular Carcinoma","enrollment":102}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":122,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oral Sorafenib","genericName":"Oral Sorafenib","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis. Used for Hepatocellular carcinoma, Renal cell carcinoma, Differentiated thyroid cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}